Michael Banov, MD
Psychiatry · Marietta, GANPI 1881771004
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $575,760 of the $732,770 with a category attached, or 78.6%. It is spread thinly across 45 manufacturers, the largest accounting for just 18.2%. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,762 payments — averaging $415.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$133K
- AbbVie$132K
- Axsome Therapeutics, Inc.$121K
- Teva Pharmaceuticals USA, Inc.$120K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109K
- Alkermes, Inc.$19K
- plus $99K from 39 others
Across 715 payments — averaging $5148.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$863K
- Livanova USA, Inc.$590K
- Teva Pharmaceuticals USA, Inc.$555K
- AbbVie$446K
- Sage Therapeutics, LLC$379K
- Janssen Research & Development, LLC$277K
- plus $572K from 10 others
What the payments were for
- Consulting fees$92,40313%
- Speaking & faculty fees$575,76079%
- Travel & lodging$32,4184%
- Food & beverage$31,9304%
- Education$2590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$132,096
- VRAYLAR$127,113
- Auvelity$118,027
- CAPLYTA$106,290
- LYBALVI$73,190
- UZEDY$45,208
- Austedo XR$38,774
- AUSTEDO$33,369
- Fanapt$16,586
- Dayvigo$15,640
- QELBREE$12,361
- LOREEV XR$8,250
- INGREZZA$7,695
- VNS Therapy Symmetry Model 8103 Generator$6,630
- ABILIFY MAINTENA$5,698
- TRINTELLIX$5,587
- QUVIVIQ$2,835
- COBENFY$1,239
- VIIBRYD$200
- VNS Therapy$101
How this compares
$732,770 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $227,807 |
| Austedo XrDeutetrabenazine | 15 | $174,988 |
| AustedoDeutetrabenazine | 18 | $101,197 |
| CaplytaLumateperone Tosylate | 40 | $67,986 |
| Invega SustennaPaliperidone Palmitate | 20 | $67,383 |
| AuvelityDextromethorphan Hbr/Bupropion | 54 | $61,349 |
| RexultiBrexpiprazole | 13 | $58,182 |
| FanaptIloperidone | 29 | $39,575 |
| BelsomraSuvorexant | 72 | $30,963 |
| VraylarCariprazine Hcl | 20 | $27,693 |
| TrintellixVortioxetine Hydrobromide | 24 | $20,942 |
| FetzimaLevomilnacipran Hcl | 29 | $17,723 |
| SaphrisAsenapine Maleate | 14 | $17,721 |
| QuviviqDaridorexant Hcl | 19 | $9,035 |
| Lurasidone Hcl | 41 | $7,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $119,904 | $276,18533 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $8,490 | $227,80728 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $109,173 | $67,98640 claims |
| Johnson & JohnsonInvega Sustenna | $133,061 | $67,38320 claims |
| AbbVieVraylar, Fetzima, Saphris | $131,553 | $63,13763 claims |
| Axsome Therapeutics, Inc.Auvelity | $120,842 | $61,34954 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $7,364 | $58,18213 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $17,663 | $39,57529 claims |
| MerckBelsomra | $244 | $30,96372 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $6,798 | $25,98337 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $3,133 | $9,03519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Marietta
- Michael UngerMarietta$35K
- Amy HollandMarietta$17K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.